Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics

Journal of Hypertension

Volumn 35, Issue , 2017, Pages S57-S63

  Weir, Matthew R ^a   Mayo, Martha R ^b   Garza, Dahlia ^b   Arthur, Susan A ^b   Berman, Lance ^b   Bushinsky, David ^c   Wilson, Daniel J ^b   Epstein, Murray ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Vifor (International) Inc   (Switzerland)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic renal insufficiency; Diuretics; Hyperkalemia; Patiromer

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BUMETANIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOOP DIURETIC AGENT; PATIROMER; PLACEBO; POTASSIUM ION; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; TORASEMIDE; CHELATING AGENT; DIURETIC AGENT; POLYMER; POTASSIUM;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIURETIC THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; AGED; BLOOD; CHEMICALLY INDUCED; COMPLICATION;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHELATING AGENTS; CONSTIPATION; DIURETICS; FEMALE; HUMANS; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; MALE; MIDDLE AGED; POLYMERS; POTASSIUM; RENAL INSUFFICIENCY, CHRONIC;

EID: 85010878247     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001278     Document Type: Article

References (29)

1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
2. Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5 Suppl 1):S1-S290.
3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147-e239.
4. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. Int J Clin Pharm 2013; 35:1099-1104.
5. McMahon GM, Mendu ML, Gibbons FK, Christopher KB. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med 2012; 38:1834-1842.
6. Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci 2014; 347:93-100.
7. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-Angiotensin-Aldosterone system. N Engl J Med 2004; 351:585-592.
8. Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam Physician 2006; 73:283-290.
9. Ingelfinger JR. A new era for the treatment of hyperkalemia? N Engl J Med 2015; 372:275-277.
10. Kovesdy CP. Management of hyperkalemia: an update for the internist. Am J Med 2015; 128:1281-1287.
11. Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet 2015; 386:1588-1598.
12. Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003; 284:F11-F21.
13. Perez GO, Pelleya R, Oster JR, Kem DC, Vaamonde CA. Blunted kaliuresis after an acute potassium load in patients with chronic renal failure. Kidney Int 1983; 24:656-662.
14. Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich) 2004; 6:532-540.
15. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol 2014; 66:185-196.
16. Wang DJ, Gottlieb SS. Diuretics: still the mainstay of treatment. Crit Care Med 2008; 36 (1 Suppl):S89-S94.
17. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319:10-24.
18. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-Acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
19. Veltassa1 (patiromer) for oral suspension [package insert]. Redwood City, CA, USA: Relypsa Inc.; 2015.
20. Li L, Harrison SD, Cope MJ, Park C, Lee L, Salaymeh F, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther 2016; 21:456-465.
21. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372:211-221.
22. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: The AMETHYST-DN randomized clinical trial. JAMA 2015; 314:151-161.
23. Helfant RH. Hypokalemia and arrhythmias. Am J Med 1986; 80 (4A):13-22.
24. Hollifield JW, Slaton PE. Thiazide diuretics, hypokalemia and cardiac arrhythmias. Acta Med Scand Suppl 1981; 647:67-73.
25. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49 (2 Suppl 2):S12-S154.
26. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431.
27. Epstein M. Hyperkalemia constitutes a constraint for implementing renin-Angiotensin-Aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney Int Suppl 2016; 6:20-28.
28. Chang TI, Zheng Y, Montez-Rath ME, Winkelmayer WC. Antihypertensive medication use in older patients transitioning from chronic kidney disease to end-stage renal disease on dialysis. Clin J Am Soc Nephrol 2016; 11:1401-1412.
29. Wheeler DC, Becker GJ, Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int 2013; 83:377-383.